Systemic Pharmacokinetic Study of T4032 (Unpreserved Bimatoprost 0.01%) Eye Gel Versus Lumigan 0.01% Eye Drops in 40 Healthy Volunteers
Latest Information Update: 20 Nov 2023
At a glance
- Drugs Bimatoprost (Primary) ; Bimatoprost
- Indications Glaucoma; Ocular hypertension
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Laboratoires Thea
- 10 Nov 2023 Status changed from not yet recruiting to completed.
- 20 Feb 2023 New trial record